Return to program book search

Session Information

WRK W016 - Adverse Drug Reactions: The Evidence and the Controversies

Tuition fee and ticket required for admission

Subject:

Date: Sunday, March 03

CME Credits: 2.00

Location: Room B118/119

Time: 3:30 PM - 5:30 PM

Director: David R. Adams, MD, PharmD, FAAD

Speakers:

  • Joel M. Gelfand, MD, MSCE, FAAD
  • Norman S. Marks - Handout
  • Neil H. Shear, MD, FAAD

Learning Objectives:
Following this course, the attendee should be able to:

  • Identify methods to prevent, diagnose and treat common and less common adverse cutaneous drug reactions.
  • Delineate the criteria which support the association of drugs with adverse cutaneous reactions.
  • Discuss the broad topic of the reporting of adverse cutaneous drug reactions inclusive of the literature, manufacturer and FDA.

Description:
Adverse cutaneous drug reactions occur in 2-3% of hospitalized patients and are also common in the outpatient setting. They are among the most common types of the 1.5 million preventable adverse drug events that annually occur in the US. This session will address gaps in knowledge and competence in preventing, diagnosing, treating, and reporting adverse cutaneous drug reactions. Case examples of both common and less common but potentially severe reactions will be presented to address gaps in quickly differentiating severe reactions from less serious reactions and in initiating appropriate treatment when indicated. To prevent these reactions from occurring, gaps in pharmaceutical knowledge about particular drugs will also be addressed. Methods to improve competence in educating patients about the safe and effective use of medication will also be discussed in the context of preventing adverse reactions. Finally, the importance of reporting adverse drug reactions and methods for doing so will be discussed.

Schedule:

Sunday, March 03
3:30 PMIntroduction and Overview with Survey / Dr. Adams
3:45 PMUnderstanding Causality Assessment: Importance and Pitfalls / Dr. Shear
4:15 PMCurrent Controversies in the Safety of Dermatologic Therapeutics / Dr. Gelfand
4:45 PMReporting to FDA MedWatch: What Happens to Your Report and How It Impacts Public Health / Dr. Marks
5:15 PMPanel Discussion with Survey / All faculty